We have highly advanced global pharmaceutical manufacturing capabilities, including active pharmaceutical ingredients (API), oral solid dose (OSD), injectables, biosimilars, and plasma products. We have fourteen manufacturing facilities, of which eleven are in India and the rest in the UK and Mexico. These facilities serve a slew of markets worldwide and produce medicines covering almost all major therapeutic areas. Our ‘Make It Better” philosophy defines our operational actions and ambitions. We strictly comply with environmental health and safety standards at each of our locations and proudly take the lead in ensuring sustainable practices.
We also have an advanced analytical lab and state-of-the-art distribution Centre in the UK. It operates two API and intermediate manufacturing facilities, each complying with regulatory requirements in the jurisdictions in which it operates. These facilities have received approval from various prominent international regulatory bodies.
We are proud to share that Intas’ has been selected by the Government of India for its Production Linked Incentive (PLI) scheme. It will add further impetus to our manufacturing ambitions. We are also boosting manufacturing capabilities and sharpening our focus on the indigenous manufacturing of critical products that our nation is currently importing. Swiftly and steadily, we are shaping up to become Atmanirbhar and a leader in this critical component of the drug supply chain. We will continue to create a world of good health, happiness, and hope.
Each pharmaceutical formulation and manufacturing facility is designed, equipped, and operated to deliver high-quality products within defined cost and delivery schedules. These manufacturing facilities have the flexibility to operate in various dosage forms and a wide range of batch sizes, whether it is solid orals, injectables, or APIs. Our strength is fuelled by early identification of molecules, building robust API processes, and targeting early launch opportunities in key markets through complete backward integration. Our first API manufacturing facility was established in 2007 to develop high-quality, cost-effective products as import substitutes through indigenous R&D. Our API manufacturing facilities are spread across four different locations and are accredited by stringent global regulatory authorities. The APIs manufactured by us are considered of global standards and are being used to manufacture finished products to supply highly regulated markets. We also have a world-class oncology formulation facility operating under global regulatory and safety standards. Our Ahmedabad SEZ caters exclusively to the US, Europe, and other regulated markets.
As a part of the progressive future strategy, we have invested in Pharmez 2 – a highly advanced expansion of our Pharmez SEZ facility in Gujarat, India. This new age, highly automated, and the efficient manufacturing unit can produce more than one billion solid orals per month and 5 million injectable units. This futuristic Pharmez 2 facility is set to be the cornerstone of our promising future.